Tau/MAP6 antagonism in neurodegeneration progression

Mechanistic description

In tauopathies, pathological tau alterations may disrupt the antagonistic balance with MAP6, causing excessive stabilization and loss of adaptive plasticity, while in other conditions the relationship may be shifted toward excess lability

Prediction: MAP6 expression levels or post-translational modifications will be altered in tauopathy patient samples as a compensatory response to tau dysfunction

Mechanism / pathway

MAP6
→
neurodegeneration

Evidence for (5)

TiME for TMEM106B.

PMID:24497553 2014 EMBO J
The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes.

PMID:24357581 2014 EMBO J
Stability properties of neuronal microtubules.

PMID:26887570 2016 Cytoskeleton (Hoboken)
ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.

PMID:28980356 2018 Dev Dyn
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

PMID:21902667 2011 Curr Pharm Des

Evidence against (2)

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response.

PMID:39257379 2024 J Cell Sci
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy.

PMID:24873720 2014 Lancet Neurol

Evidence matrix

6 supporting 2 contradicting

53% posterior support

Supporting

In tauopathies, pathological tau alterations may disrupt the antagonistic balance with MAP6, causing excessive stabilization and loss of adaptive plasticity, while in other conditions the relationship may be shifted toward excess lability
TiME for TMEM106B. PMID:24497553 · 2014 · EMBO J
The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. PMID:24357581 · 2014 · EMBO J
Stability properties of neuronal microtubules. PMID:26887570 · 2016 · Cytoskeleton (Hoboken)
ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins. PMID:28980356 · 2018 · Dev Dyn
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). PMID:21902667 · 2011 · Curr Pharm Des

Contradicting

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response. PMID:39257379 · 2024 · J Cell Sci
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy. PMID:24873720 · 2014 · Lancet Neurol

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Tau/MAP6 antagonism in neurodegeneration progression. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-a0b246fc70da

BibTeX

@misc{scidex_hypothesis_ha0b246f,
  title        = {Tau/MAP6 antagonism in neurodegeneration progression},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-a0b246fc70da},
  note         = {SciDEX artifact hypothesis:h-a0b246fc70da}
}